Calliditas Therapeutics IPO Presentation Deck

Consistent trends support selection of 16 mg versus 8 mg NEFIGAN trial. calliditas UPCR (interim) Total 24-hour urine protein Urinary albumin creatinine ratio Total 24-hour urine albumin P-Creatinine Microhematuria proportion Placebo 3% 1% 86% 9 Months Nefecon (16 mg) (27%) (30%) (28%) (33%) (2%) 63% Nefecon (8 mg) (22%) (20%) (14%) (18%) (1%) 82% We selected 16mg dose for evaluation in our pivotal Phase 3 clinical trial June 2020 35

View entire presentation